Servier shared a post on LinkedIn:
“At Servier, we have been committed to fighting cancer for many years. Oncology is a major therapeutic priority for us, accounting for close to 70% of our R&D investments.
We currently have a portfolio of 8 medicines available to healthcare professionals and patients. Our major investments in the cancer are demonstrated through our robust pipeline of 33 oncology R&D projects.
Learn more about Servier.”
More posts featuring Servier.